Browsing Health Sciences by Subject "Efavirenz"
Now showing items 1-5 of 5
-
Bio-behavioural evaluation of efavirenz and Δ9-tetrahydrocannabinol alone and in combination in rats with respect to psychosis and anxiety
(North-West University (South-Africa), 2019)The highly active antiretroviral therapy, efavirenz (EFV), has been noted to occur as a constituent of a potent new designer drug cocktail called “Nyaope” or “Whoonga”, which is reported to have mind-altering and addictive-like ... -
The development of efavirenz and praziquantel amorphous solid dispersions
(North-West University (South-Africa), 2019)Many active pharmaceutical ingredients (API) that are highly permeable, have low aqueous solubility. Such APIs are classified as Biopharmaceutics classification system (BCS) class II drugs. Efavirenz and praziquantel both ... -
Evaluation of efavirenz on neurochemical and oxidative stress markers and addictive-like behaviours in rats
(North-West University, 2018)HIV positive patients treated with the antiretroviral (ARV) drug efavirenz have been observed to experience various neuropsychiatric symptoms including insomnia, dizziness, somnolence, vivid and abnormal dreams and thoughts ... -
Population pharmacokinetic and pharmacodynamic study of efavirenz in HIV–1–infected children treated with first line antiretroviral therapy in South Africa
(North-West University, 2011)Highly active antiretroviral therapy (HAART) has improved the life expectancy of HIV–1–infected patients dramatically since it was launched in 1996, but there are still many challenges in the provision of HAART, especially ... -
Quality and safety implications of efavirenz and pyrimethamine crystal modifications
(2014)This study focused on two active pharmaceutical ingredients (APIs) that are used to treat two of the most notorious diseases in Africa, i.e. human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) and ...
